EUCTR2012-005661-13-GB进行中（未招募）1 期
ong-Term Safety and Efficacy of ABT-126 in Subjects with Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study M10-855
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 430
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- The subject was randomized into Study M10-855 and completed through Week 26 in that study.
- •- The subject is receiving one or more antipsychotic medications.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 430
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Additional history collected during participation in Study M10-855 provides evidence that, in the investigator's judgement, the subject does not have schizophrenia.
- •- The subject experienced an adverse event or abnormal finding during physical examination, vital signs, laboratory profile, and/or electrocardiogram (ECG) measurements in Study M10-855 that indicates the subject is likely to become medically unstable during the current study.
- •- The subject is currently taking or is expected to be prescribed any excluded medication without the approval of AbbVie medical monitor.
- •- The subject is currently enrolled in, or plans to participate in, another interventional study during the course of this trial.
研究者
相似试验
进行中（未招募）
不适用
ong-Term Safety and Tolerability of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completing Study M11-793Alzheimer's diseaseEUCTR2012-000537-39-DEAbbVie Deutschland GmbH & Co. KG400
进行中（未招募）
不适用
ong-Term Safety and Tolerability of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completing Study M11-793Alzheimer's diseaseMedDRA version: 16.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2012-000537-39-GBAbbVie Deutschland GmbH & Co. KG400
进行中（未招募）
不适用
ong-Term Safety and Tolerability of ABT-126 in Subjects with Mild-to-Moderate Alzheimer’s Disease: An Open-Label Extension Study for Subjects Completing Study M10-985.EUCTR2011-004780-75-GBAbbVie Deutschland GmbH & Co. KG400
进行中（未招募）
不适用
ong-Term Safety and Tolerability of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completing Study M11-793MedDRA version: 14.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Alzheimer's diseaseEUCTR2012-000537-39-GRAbbott GmbH & Co. KG400
进行中（未招募）
1 期
Ph2 study of chemotherapy plus ABT-165 compared to chemotherapy plus bevacizumab in people with metastatic colorectal (bowel) cancermetastatic adenocarcinoma of the colon or rectum previously treated with a regimen containing fluoropyrimidine/oxaliplastin and bevacizumabEUCTR2017-003669-87-ESAbbvie Deutschland GmbH & Co. KG100